Bloomberg BNA’s Pharmaceutical Law & Industry Report was recently released, and according to attorneys the recent FDA approval of the first 3D printed drug could lead to several complicated legal, product liability and intellectual property clashes that could derail the new technology before it even begins. Several lawyers explained to Bloomberg that using a 3D printing process for pills and drugs could potentially cause difficulties with identifying the actual manufacturer of the patented drug product. Additionally it is noted that legally it’d be tough to ascertain who would be considered the maker, specifically related to accountability issues.
- Hardcotton’s Pressure Controlled SLA 3D Printer
- CRP to present 3D-printed products for space industry